Sign in Subscribe

braf

A collection of 55 issues

Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer In a study of 1,391 patients, those with persistent or acquired RAS and BRAF mutations in ctDNA had significantly worse overall survival than patients who maintained wild-type status, suggesting liquid biopsy monitoring

CRC Research Update — August 19, 2026

Today's colorectal cancer research highlights

WNT Pathway Activation Drives Immune Evasion in BRAF-Mutant Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH WNT Pathway Activation Drives Immune Evasion in BRAF-Mutant Colorectal Cancer Researchers using mouse models and organoids found that WNT pathway activation promotes malignant transformation and immune evasion in microsatellite-stable BRAF-mutant colorectal cancer. (Gastroenterology) This content is informational only and does not constitute medical

BREAKWATER Cohort 3: Encorafenib, Cetuximab, and FOLFIRI Tested in BRAF V600E-Mutant CRC

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER Cohort 3: Encorafenib, Cetuximab, and FOLFIRI Tested in BRAF V600E-Mutant CRC A randomized study compared encorafenib plus cetuximab and FOLFIRI against FOLFIRI with or without bevacizumab in patients with BRAF V600E-mutant colorectal cancer. (Annals of Oncology) This content is informational only

CRC Research Update — August 13, 2026

Today's colorectal cancer research highlights

Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer

Skip to content The CRC Digest ▸ TREATMENT Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer A patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer responded to re-challenge with encorafenib and cetuximab combined with nivolumab after prior progression, suggesting this combination may offer renewed

Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition

Skip to content The CRC Digest ▸ TREATMENT Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition A 60-year-old male patient diagnosed in 2019 with BRAF-mutant metastatic CRC and peritoneal metastases experienced an extraordinary response to MEK inhibitor-based treatment. (Frontiers in Oncology) This content

CRC Research Update — July 19, 2026

Today's colorectal cancer research highlights

BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer This randomized study evaluated targeted therapy combinations specifically for patients with BRAF V600E mutations, a subtype associated with poorer outcomes. (Annals of Oncology) This

Precision oncology strategies beyond RAS and RAF in MSS colorectal cancer

Skip to content The CRC Digest Precision oncology strategies beyond RAS and RAF in MSS colorectal cancer Review outlines next-generation precision approaches for microsatellite-stable tumors, including antibody-drug conjugates, bispecific antibodies, DNA damage response targeting, and tumor microenvironment-directed therapies. (ESMO Open) This content is informational only and does not constitute medical